MARKET INTRODUCTION
Castration-resistant prostate cancer (CRPC) is a type of cancer that occurs in men who have undergone androgen deprivation therapy (ADT) and is regardless of castrate levels of testosterone. The cancer is seen among many older men as there is a rapidly rising PSA level resulting in metastatic CRPC.
MARKET DYNAMICS
The castration-resistant prostate cancer (CRPC) therapeutics market growth is expected to grow due to growing geriatric population, rising incidences of prostate disorders and cancers, and growing demand for biopharmaceutical based products for prostate cancer. The development and investment of precision medicines for prostate cancer treatment is expected to serve growth opportunities for the market growth.
MARKET SCOPE
The "Castration-resistant Prostate Cancer (CRPC) Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of castration-resistant prostate cancer (CRPC) therapeutics market with detailed market segmentation by therapy, route of administration, and distribution channel. The castration-resistant prostate cancer (CRPC) therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in castration-resistant prostate cancer (CRPC) therapeutics market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The castration-resistant prostate cancer (CRPC) therapeutics market is segmented on the basis of, therapy, route of administration, and distribution channel. Based on therapy, the market is divided into chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. Based on route of administration the market is classified as injectable, and oral. And based on distribution channel, the market is classified as hospital and retail pharmacies, and online distribution.

REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the castration-resistant prostate cancer (CRPC) therapeutics market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The castration-resistant prostate cancer (CRPC) therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting castration-resistant prostate cancer (CRPC) therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the castration-resistant prostate cancer (CRPC) therapeutics market in these regions.

MARKET PLAYERS
The report covers key developments in the castration-resistant prostate cancer (CRPC) therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from castration-resistant prostate cancer (CRPC) therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for castration-resistant prostate cancer (CRPC) therapeutics in the global market. Below mentioned is the list of few companies engaged in the castration-resistant prostate cancer (CRPC) therapeutics market.
The report also includes the profiles of key players in castration-resistant prostate cancer (CRPC) therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Bayer AG
- AbbVie Inc.
- Johnson and Johnson
- Sanofi
- Amgen Inc.
- Novartis AG
- OncoGenex Technologies Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Astellas Pharma Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.